- Clinical data highlight survival benefits and improvement in functional motor outcomes associated with treatment with doxecitine (dC) and doxribtimine (dT) – an investigational pyrimidine nucleoside therapy – in people living with thymidine kinase 2 deficiency (TK2d).1,2,3
- Additional patient experience data emphasize the profound physical challenges and severe psychological strain that come with living with TK2d, and the heavy emotional and physical burden experienced by caregivers.4,5
- Across all study populations, pyrimidine nucleoside and/or nucleotide therapy was generally well tolerated.1,2,3
- TK2d is an ultra-rare, life-threatening, genetic mitochondrial disease with no currently approved treatment options.6,7,8,9,10,11
BRUSSELS, March 19, 2025 /PRNewswire/ — UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with thymidine kinase 2 deficiency (TK2d), at this year’s MDA Clinical and Scientific Conference, Dallas, Texas, March 16-19, 2025.
The data show that …